Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | EVP, CHIEF HR OFFICER | February 28, 2025 | March 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date February 28, 2025 · Filed March 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, $0.01 par valueSEC Table I · non-derivative | Direct | 6,130 |
Ending reported balance
After 2025-03-03 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-02-28 · Tax withholding · Disposed 16,904 · Balance 27,380 Row 2 · 2025-03-03 · Sale · Disposed 5,677 · Balance 21,703 F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.16 to $210, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2025-03-03 · Sale · Disposed 14,973 · Balance 6,730 F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.25 to $211.23, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2025-03-03 · Sale · Disposed 600 · Balance 6,130 F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.3 to $211.4, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.16 to $210, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.25 to $211.23, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.3 to $211.4, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 22,993 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001516 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,993 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:01 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 50,350 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001179110-21-010695 · edgar.xml · derivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 50,350 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:01 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 50,350 | $120.00 | $6,042,000.00 |
DisclosureSEC source: 0001179110-21-010695 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:01 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 50,350 | $58.88 | $2,964,608.00 |
DisclosureSEC source: 0001179110-21-010695 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:31 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 19,514 | $108.59 | $2,119,040.87 |
DisclosureSEC source: 0001179110-21-002607 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.285 to $108.83, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:31 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 15,524 | $107.74 | $1,672,555.76 |
DisclosureSEC source: 0001179110-21-002607 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,514 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption(right to buy) · Derivative | 42,236 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002051 · edgar.xml · derivative · entry 5 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,236 Underlying: Common stock · 42,236 shares Expires 2031-02-17 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,079 on February 18, 2022, 14,079 on February 18, 2023, and 14,078 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 11,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002051 · edgar.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,038 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002051 · edgar.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,060 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002051 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,062 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 13,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002051 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,957 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| November 27, 2020 Filed Dec 1, 2020 22:22 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 51,990 | $0.00 Strike: $51.42 | $0.00 |
DisclosureSEC source: 0001179110-20-011502 · edgar.xml · derivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 51,990 shares Expires 2024-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 27, 2020 Filed Dec 1, 2020 22:22 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 51,990 | $105.00 | $5,458,950.00 |
DisclosureSEC source: 0001179110-20-011502 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 27, 2020 Filed Dec 1, 2020 22:22 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 51,990 | $51.42 | $2,673,325.80 |
DisclosureSEC source: 0001179110-20-011502 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 7, 2020 21:01 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 19,445 | $85.00 | $1,652,825.00 |
DisclosureSEC source: 0001179110-20-005551 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:55 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 15,462 | $85.42 | $1,320,764.04 |
DisclosureSEC source: 0001179110-20-002860 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,445 Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:01 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 78,559 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001179110-20-002132 · edgar.xml · derivative · entry 5 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,559 Underlying: Common Stock · 78,559 shares Expires 2030-02-19 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,187 on February 20, 2021, 26,186 on February 20, 2022, and 26,186 on February 20, 2023. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:01 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002132 · edgar.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,907 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:01 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,104 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002132 · edgar.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,908 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:01 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 6,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002132 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,804 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:01 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 18,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002132 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,964 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| September 27, 2019 Filed Oct 1, 2019 21:52 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 15,515 | $75.02 | $1,163,873.24 |
DisclosureSEC source: 0001104659-19-052312 · a4.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.02, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:57 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 12,345 | $79.41 | $980,316.45 |
DisclosureSEC source: 0001179110-19-003086 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,515 Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:19 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 30,763 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002367 · edgar.xml · derivative · entry 5 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,763 Underlying: Common Stock · 30,763 shares Expires 2029-02-20 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,255 on February 21, 2020, 10,254 on February 21, 2021, and 10,254 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:19 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 4,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002367 · edgar.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,860 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:19 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 6,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002367 · edgar.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,755 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:19 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 7,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002367 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,915 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:19 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 9,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002367 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,835 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 23:58 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 17,588 | $99.47 | $1,749,485.40 |
DisclosureSEC source: 0001179110-18-008819 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.19 to $99.58, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:30 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 18,129 | $118.67 | $2,151,451.82 |
DisclosureSEC source: 0001179110-18-003338 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,588 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.58 to $118.84, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:30 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 12,183 | $118.26 | $1,440,761.58 |
DisclosureSEC source: 0001179110-18-003338 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,717 Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:54 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 22,210 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002299 · edgar.xml · derivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,210 Underlying: Common Stock · 22,210 shares Expires 2028-02-14 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 7,404 on February 15, 2019, 7,403 on February 15, 2020, and 7,403 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:54 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 6,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002299 · edgar.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,900 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:54 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 7,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002299 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,060 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:54 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 7,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002299 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,158 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 23:09 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 87,040 | $0.00 Strike: $35.88 | $0.00 |
DisclosureSEC source: 0001179110-17-015664 · edgar.xml · derivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 87,040 shares Expires 2023-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 23:09 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 87,040 | $98.45 | $8,569,053.18 |
DisclosureSEC source: 0001179110-17-015664 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,078 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.13 to $98.86, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 23:09 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 87,040 | $35.88 | $3,122,995.20 |
DisclosureSEC source: 0001179110-17-015664 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2017 Filed Mar 10, 2017 22:21 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 22,451 | $65.29 | $1,465,825.79 |
DisclosureSEC source: 0001179110-17-004439 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,078 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:13 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 18,902 | $62.22 | $1,176,082.44 |
DisclosureSEC source: 0001179110-17-003704 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,529 Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 45,700 | $0.00 Strike: $61.36 | $0.00 |
DisclosureSEC source: 0001179110-17-002811 · edgar.xml · derivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,700 Underlying: Common stock · 45,700 shares Expires 2027-02-15 F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 15,234 on 02/16/2018, 15,233 on 02/16/2019, and 15,233 on 02/16/2020. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 7,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002811 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,431 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 15,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002811 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,351 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| May 10, 2016 Filed May 12, 2016 21:43 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 21,583 | $63.52 | $1,370,952.16 |
DisclosureSEC source: 0001179110-16-024455 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,615 Read SEC document |
| March 01, 2016 Filed Mar 2, 2016 22:23 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 10,792 | $55.00 | $593,560.00 |
DisclosureSEC source: 0001179110-16-020680 · edgar.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,198 Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 22:23 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 2,074 | $55.32 | $114,737.83 |
DisclosureSEC source: 0001179110-16-020680 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,990 Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 22:23 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 27,890 | $56.00 | $1,561,840.00 |
DisclosureSEC source: 0001179110-16-020680 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,064 Read SEC document |
| February 18, 2016 Filed Feb 22, 2016 22:08 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 42,370 | $0.00 Strike: $54.86 | $0.00 |
DisclosureSEC source: 0001179110-16-019783 · edgar.xml · derivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,370 Underlying: Common stock · 42,370 shares Expires 2026-02-17 F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 14,124 on 02/18/2017, 14,123 on 02/18/2018, and 14,123 on 02/1/8/2019. Read SEC document |
| March 02, 2015 Filed Mar 3, 2015 23:07 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 12,314 | $60.30 | $742,534.20 |
DisclosureSEC source: 0001179110-15-004096 · edgar.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,954 Read SEC document |
| February 28, 2015 Filed Mar 3, 2015 23:07 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 4,592 | $60.50 | $277,816.00 |
DisclosureSEC source: 0001179110-15-004096 · edgar.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,268 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.